Clinical Trials Browser

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT03896269 2026-02-20

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Phase 1 Recruiting

38 enrolled

Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

NCT06950034 2026-02-09

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Phase 1 Recruiting

105 enrolled

Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06712810 2025-10-10

Q702 for the Treatment of Patients With Hematologic Malignancies

Phase 1 Recruiting

46 enrolled

DermatologicLymphoidMyeloidOther hematologic neoplasmSarcoma

Blastic Plasmacytoid Dendritic Cell Neoplasm, Histiocytosis, Langerhans-Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Erdheim-Chester Disease, Dendritic Cell Sarcoma, Interdigitating, Histiocytic Sarcoma, Primary Myelofibrosis

NCT05233618 2025-05-28

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

Phase 1 Recruiting

44 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT06462365 2025-04-15

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Phase 1 Recruiting

36 enrolled

LymphoidMyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05488548 2025-01-14

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Phase 1 Recruiting

75 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT06218628 2024-05-03

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Phase 1 Recruiting

24 enrolled

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Clinical Trials

CELESTIAL-MDS

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

CROSSCHECK-001

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Q702 for the Treatment of Patients With Hematologic Malignancies

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition